Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Chongqing Lummy Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company specializing in the research, development, and manufacturing of traditional Chinese medicine and modern pharmaceuticals. The company operates primarily in the domestic market, leveraging its strong distribution network and established brand reputation to drive sales of its key products, including anti-inflammatory and analgesic medications.
Chongqing Lummy generates revenue through the sale of prescription and over-the-counter medications, focusing on traditional Chinese medicine formulations. Its competitive advantages include a robust R&D pipeline and a strong brand presence in the domestic market, allowing for premium pricing on certain products.
Changes in regulatory approval timelines for new drug formulations
Market share shifts in the Chinese pharmaceutical sector
Fluctuations in raw material costs impacting production margins
Consumer sentiment towards traditional medicine products
Regulatory changes affecting drug approval processes
Technological disruption in drug development methodologies
Increased competition from domestic and international pharmaceutical companies
Potential market entry of generic alternatives to Lummy's products
Negative net margins indicating potential liquidity issues if losses persist
Limited cash flow generation impacting ability to fund R&D initiatives
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but consumer spending on healthcare can be affected by broader economic conditions.
Interest rates have minimal direct impact on Lummy's operations, but rising rates could increase borrowing costs for R&D financing, potentially affecting future growth.
minimal - The company has a low debt-to-equity ratio of 0.15, indicating limited reliance on external financing.
value - Investors may be attracted to Lummy due to its low valuation metrics despite current operational challenges.
moderate - The stock has shown some volatility, with a 1-year return of 32.1%, indicating potential for price fluctuations.
